Aequita Pharmacy Review: Compounded GLP-1s & Safety

Last updated: October 29, 2026

Quick Answer

This Aequita Pharmacy Review: Compounded GLP-1s & Safety covers what you need to know before ordering compounded semaglutide or tirzepatide from this Kirkland, Washington compounding pharmacy. Aequita has supplied GLP-1 injectables to telehealth programs like Mochi Health, but a 2026 state inspection flagged serious safety concerns, and federal rules now sharply limit mass compounding of these drugs. If you’re weighing compounded GLP-1s for weight loss, you need to understand both the regulatory picture and the real-world risks before you order.

A pharmacist in Kirkland, Washington compounds weight-loss injections most days of the week, and in 2026, that pharmacy became the center of a public safety dispute. Aequita Pharmacy, a 503A compounding facility, produces semaglutide and tirzepatide injectables for telehealth weight-loss programs, including Mochi Health. This Aequita Pharmacy Review: Compounded GLP-1s & Safety walks through what the pharmacy does, what regulators found, and what that means if you’re considering compounded GLP-1 medication for appetite control or metabolic health. You’ll get a clear picture of costs, risks, prescription requirements, and how Aequita compares with other compounded GLP-1 providers.

Key Takeaways

• Aequita Pharmacy is a 503A compounding pharmacy in Kirkland, Washington that produces compounded semaglutide and tirzepatide, largely for telehealth clients like Mochi Health.
• In June 2026, Washington’s Department of Health issued Aequita a “Notice of Immediate Jeopardy” after whistleblower complaints about Mochi Health’s weight-loss program [1].
• FDA ended broad enforcement discretion for mass-compounded GLP-1s on May 22, 2025, meaning most compounding pharmacies can now only fill patient-specific prescriptions, not mass-produce doses [2][3][4].
• As of mid-2025, federal regulators had logged over 600 adverse event reports each for compounded semaglutide and compounded tirzepatide, including hospitalizations from dosing errors [5].
• Compounded GLP-1s are not FDA-approved products; they skip premarket safety, purity, and effectiveness review that brand-name drugs undergo [6].
• Dosing errors are common because compounded versions often come in multi-dose vials requiring manual measurement, unlike brand-name pens [7][8].
• Cheaper price does not mean equal safety, compounded versions can vary in potency and may use unapproved salt forms of the active ingredient [8].

What Is Compounded GLP-1 and How Does It Work

Compounded GLP-1 medication is a custom-made version of drugs like semaglutide or tirzepatide, mixed by a licensed pharmacy rather than manufactured by Novo Nordisk or Eli Lilly. It works the same way pharmacologically, activating GLP-1 receptors to slow digestion, reduce appetite, and improve blood sugar control, but it is not reviewed or approved by the FDA as a finished product [6].

Pharmacies compound these drugs in two main ways:

• 503A pharmacies (like Aequita) compound for individual patients based on a specific prescription.
• 503B outsourcing facilities produce larger batches under somewhat stricter manufacturing standards, but these facilities lost broad permission to mass-produce GLP-1s once the FDA shortage declaration ended on May 22, 2025 [2][3].

The active ingredient in compounded versions is sometimes a salt form, such as semaglutide sodium, rather than the base form used in Ozempic or Wegovy. Regulators have flagged these salt forms as not clinically studied for safety or effectiveness at the same level as the approved drug [8].

Decision rule: Choose compounded GLP-1 only if you have a documented medical reason (such as drug shortage, allergy to an inactive ingredient, or dose customization need) and a prescription written specifically for you, not a mass-order through a telehealth subscription with no individualized medical review.

Is Aequita Pharmacy Safe and Legitimate

Aequita Pharmacy is a licensed 503A compounding pharmacy, but a 2026 state health inspection raised serious concerns about its safety practices. “Legitimate” in the licensing sense does not automatically mean “safe” in the clinical sense, and Aequita’s case shows why that distinction matters.

In June 2026, the Washington State Department of Health inspected Aequita following whistleblower reports tied to Mochi Health’s weight-loss drug program and issued a “Notice of Immediate Jeopardy”, a designation normally reserved for conditions posing an immediate, serious risk to patient health [1]. This is not a routine paperwork violation; it signals regulators found conditions serious enough to warrant urgent corrective action.

Aequita’s core business includes compounding semaglutide and tirzepatide injections plus other customized preparations, so GLP-1 weight-loss drugs are a central part of its operations, not a side project.

Common mistake: Assuming a pharmacy’s state license or “FDA-registered facility” label means every batch is tested and safe. Compounding pharmacies are inspected periodically, but they don’t undergo the same premarket review as brand-name drug manufacturers [6]. For a broader look at how other compounding pharmacies in this space stack up, see this compound pharmacy GLP-1 reviews roundup.

How Much Does Compounded GLP-1 From Aequita Cost

Compounded GLP-1 pricing through telehealth partners like Mochi Health typically runs lower than brand-name list prices, but exact Aequita pricing isn’t publicly standardized and varies by dose, provider markup, and subscription terms [VERIFY: current Aequita/Mochi Health pricing]. Brand-name Ozempic and Wegovy often list well above $900,$1,300 per month without insurance, which is why compounded alternatives attract cost-conscious shoppers.

Because pricing structures shift often and Aequita doesn’t sell directly to consumers (it fills prescriptions through telehealth intermediaries), always confirm current costs, shipping fees, and subscription cancellation terms directly with the telehealth provider before paying. For a side-by-side look at how compounded GLP-1 costs compare across providers, see this MaxLife compounded semaglutide price and legitimacy review.

Compounded GLP-1 vs Brand Name Ozempic: Which Is Better

Brand-name Ozempic and Wegovy are generally the safer, better-studied choice because they went through FDA clinical trials and premarket review; compounded versions trade some of that safety assurance for lower cost and easier access. Neither option is universally “better”, it depends on your budget, access to insurance, and risk tolerance.

Factor	Brand-Name GLP-1 (Ozempic/Wegovy)	Compounded GLP-1 (e.g., via Aequita)
FDA approval	Yes, as a finished product	No premarket review [6]
Dosing format	Pre-filled pen, fixed dose	Often vial and syringe, manual measurement [7]
Active ingredient	Approved base form	Sometimes salt form (e.g., semaglutide sodium) [8]
Cost	Higher, but insurance may cover	Often lower out-of-pocket [VERIFY current pricing]
Adverse event tracking	Extensive post-market surveillance	Growing but still limited adverse event data [5][9]

Choose brand-name if: you have insurance coverage, a history of dosing errors, or any underlying condition where precise dosing matters most.

Choose compounded if: you have a documented, individualized prescription need and you understand the quality-control tradeoffs. You can also read about compounded semaglutide injections and compounded tirzepatide injections for more detail on how each is prepared.

Do I Need a Prescription for Aequita Pharmacy GLP-1

Yes, you need a valid prescription to receive compounded GLP-1 medication from Aequita Pharmacy. Aequita fills orders through telehealth partners, which means a licensed provider must evaluate you and issue a patient-specific prescription before any medication ships.

Red flags that suggest a provider isn’t following proper prescribing standards include:

• No video or phone consultation before prescribing
• No review of your medical history or current medications
• Automatic approval regardless of your BMI or health profile
• Pressure to subscribe to recurring shipments before you’ve even spoken with a clinician

Edge case: If a telehealth site offers GLP-1 medication with zero clinical screening, that’s a sign of a program cutting corners, exactly the kind of practice that triggered scrutiny of Mochi Health and, by extension, Aequita [1].

Aequita Pharmacy GLP-1 Reviews and Side Effects

Independent reviews of Aequita-supplied GLP-1 products describe the same general side effect profile as other GLP-1 drugs, but with added risk from dosing inconsistency. Nausea, vomiting, diarrhea, constipation, and abdominal pain are the most commonly reported effects, and some cases have been severe enough to require hospitalization [5].

By July 31, 2025, the FDA had logged 605 adverse event reports tied to compounded semaglutide and 545 tied to compounded tirzepatide nationally, not limited to any single pharmacy [5]. A separate analysis reported more than 1,000 combined adverse events by mid-2025, including overdoses, injection-site reactions, and hospitalizations linked to compounding errors and inconsistent active ingredient forms [9].

Quick example: A patient using a vial-and-syringe compounded product may misread “units” dosing instructions and inject 5 to 20 times the intended amount, a documented pattern behind many adverse event reports [7].

Are Compounded GLP-1s FDA Approved and Regulated

No. Compounded GLP-1 medications are not FDA-approved as finished drug products. They are prepared under pharmacy compounding rules, which involve different oversight than the clinical trial and manufacturing review process required for approved drugs [6].

Key regulatory facts to know:

• FDA ended broad enforcement discretion allowing mass compounding of semaglutide and tirzepatide on May 22, 2025, once shortages resolved [2][3][4].
• After that date, compounding is supposed to be limited to narrow, patient-specific situations, not high-volume production for telehealth subscription programs [2][4].
• FDA has sent warning letters to more than 50 GLP-1 compounders and manufacturers for falsely marketing compounded products as “generic” equivalents with the same safety and efficacy as approved drugs.
• Telehealth companies are barred from claiming compounded drugs are “clinically proven” or equivalent to the FDA-approved product, per FDA guidance issued June 15, 2026 [6].

This regulatory tightening is exactly why Aequita’s case drew attention: a large-volume supplier to a telehealth program sits in a gray zone regulators are actively cracking down on.

Other Compounded GLP-1 Pharmacies Besides Aequita

Aequita isn’t the only compounding pharmacy serving the GLP-1 weight-loss market, and comparing options can help you spot red flags faster. Other providers operate under similar 503A or 503B structures, with varying levels of transparency about sourcing and quality control.

Some comparison points worth checking across any compounding pharmacy:

• Is the active ingredient the FDA-approved base form or a salt form?
• Does the pharmacy publish third-party testing results?
• Is there a licensed pharmacist available for questions?
• Does the telehealth partner require a real medical consultation?

For comparison shopping, you can review other provider breakdowns like Medvi’s GLP-1 weight-loss-only program, Measured’s GLP-1 cost and weight loss review, or LevelsRx’s GLP-1 weight loss review.

How Effective Is Compounded GLP-1 for Weight Loss

Compounded GLP-1 products are expected to work similarly to brand-name versions because they contain the same or a closely related active molecule, but effectiveness data specific to compounded formulations is far more limited than the clinical trial evidence behind approved drugs. Brand-name semaglutide and tirzepatide have extensive trial data (such as the STEP and SURMOUNT trial programs) showing significant average weight loss over 68-72 weeks. Compounded versions haven’t been through that same trial process, so individual results can vary more, and consistency between batches isn’t guaranteed [6][8].

Decision rule: If consistent, predictable dosing matters most to you, for example, if you’ve had side effects from dosing variability before, brand-name formulations carry a stronger evidence base.

Who Should Not Take Compounded GLP-1

People with a personal or family history of medullary thyroid carcinoma, those with Multiple Endocrine Neoplasia syndrome type 2, pregnant or breastfeeding individuals, and anyone with a known allergy to GLP-1 drug components should not take compounded or brand-name GLP-1 medication without specialist guidance. This applies regardless of whether the product comes from Aequita or any other pharmacy.

Additional caution is warranted for:

• Anyone with a history of pancreatitis
• People with severe gastrointestinal disease
• Patients already on insulin or sulfonylureas, due to hypoglycemia risk
• Anyone unable to reliably self-administer a measured injection from a multi-dose vial [7]

Talk to a licensed healthcare provider before starting any GLP-1 medication, compounded or brand-name, especially if you fall into one of these categories.

Why Is Compounded GLP-1 Cheaper Than Brand Name

Compounded GLP-1 is cheaper mainly because it skips the clinical trial costs, patent protections, and FDA approval process that brand-name manufacturers factor into their pricing. Compounding pharmacies also often use bulk active pharmaceutical ingredient sourced separately rather than a finished, patented formulation.

That lower cost comes with tradeoffs:

• No guarantee of the same purity or potency standards as FDA-approved manufacturing [8]
• Possible use of salt forms not validated in large clinical trials [8]
• Variable quality control between compounding batches and even between pharmacies [9]

Common mistake: Assuming “cheaper” automatically means “same drug, lower markup.” In reality, cost differences often reflect differences in regulatory burden and testing rigor, not just profit margins.

How Long Does It Take to Receive GLP-1 From Aequita

Delivery timelines for compounded GLP-1 through telehealth partners typically range from a few days to about two weeks after a prescription is approved, though exact shipping times depend on the specific telehealth provider and current demand [VERIFY: current Aequita/Mochi Health shipping timelines]. Cold-chain shipping requirements for injectable GLP-1 products can also affect delivery windows, especially during high-demand periods.

Always confirm current shipping estimates directly with your telehealth provider before relying on a specific delivery date, particularly if you’re transitioning off another medication and don’t want a gap in treatment.

What Happens if Compounded GLP-1 Doesn’t Work

If compounded GLP-1 isn’t producing expected appetite control or weight loss after a reasonable trial period (often 8-12 weeks at a stable dose), the right move is to contact your prescribing provider rather than self-adjusting the dose. Unlike brand-name pens with fixed dosing, compounded vials make it tempting to simply inject more, a decision that significantly raises overdose risk [7].

Steps to take if it isn’t working:

1. Confirm you’re using the correct injection technique and storage conditions.
2. Review whether the dose has been titrated appropriately over time.
3. Ask your provider whether a different formulation (semaglutide vs. tirzepatide) might suit you better.
4. Discuss whether switching to a brand-name product is a safer option given your response.

Edge case: Sometimes “not working” actually means inconsistent potency between batches, a known risk with compounded products that doesn’t exist with FDA-approved pens [8].

Common Mistakes People Make With Compounded GLP-1

The most common mistakes involve dosing errors, skipping medical screening, and misunderstanding what “compounded” actually means. These mistakes account for a large share of the adverse events regulators have tracked [5][7][9].

Watch for these specific pitfalls:

• Misreading units-based dosing instructions, leading to accidental overdose of 5 to 20 times the intended amount [7]
• Assuming “compounded” means “generic”, compounded drugs are not FDA-approved generics and shouldn’t be marketed that way
• Skipping a real medical consultation because a website made ordering too easy
• Ignoring Notice of Immediate Jeopardy-type findings at a supplying pharmacy, instead of asking the telehealth provider direct questions about their pharmacy partners
• Self-adjusting doses without provider input when side effects or lack of progress occur

If you’re researching alternatives to compounded products, it’s worth reading about FDA-approved GLP-1 brands versus compounded options and whether a generic version of Ozempic exists before committing to any compounded source.

FAQ

Is Aequita Pharmacy FDA approved?
No single pharmacy product is “FDA approved” in the compounding sense. Aequita operates as a licensed 503A compounding pharmacy, but its compounded GLP-1 products don’t go through the FDA premarket review that brand-name drugs require [6].

What drug does Aequita Pharmacy make for Mochi Health?
Aequita compounds semaglutide and tirzepatide injectables that are distributed through Mochi Health’s telehealth weight-loss program, alongside other customized pharmacy preparations.

Why did Washington State investigate Aequita Pharmacy?
The Washington Department of Health inspected Aequita after whistleblower reports about Mochi Health’s weight-loss drug program and issued a Notice of Immediate Jeopardy in June 2026, a designation used for serious, immediate patient health risks [1].

Can I still legally get compounded semaglutide in 2026?
Yes, but only under narrower conditions than before. Since May 22, 2025, FDA has restricted mass compounding of semaglutide and tirzepatide, limiting it mostly to individualized, patient-specific prescriptions [2][3][4].

Is compounded tirzepatide as effective as Zepbound or Mounjaro?
It’s expected to work through the same mechanism, but compounded tirzepatide hasn’t gone through the same clinical trials as Zepbound or Mounjaro, so effectiveness and consistency can vary [6][8].

What are the biggest risks of compounded GLP-1 medication?
The biggest risks are dosing errors from manual measurement, inconsistent potency between batches, and use of unapproved salt forms of the active ingredient [7][8].

How do I know if a GLP-1 telehealth provider is trustworthy?
Look for a real medical consultation, transparency about which pharmacy compounds the medication, and clear information about the active ingredient form used. Avoid providers that skip clinical screening entirely.

Should I choose brand-name GLP-1 over compounded if I can afford it?
If cost isn’t a barrier, brand-name GLP-1 medication generally offers a stronger safety and effectiveness track record because it has gone through FDA clinical trials and premarket review [6].

Conclusion

Aequita Pharmacy sits at the center of a legitimate but increasingly scrutinized corner of the GLP-1 weight-loss market. It’s a licensed compounding pharmacy supplying real telehealth programs, but a 2026 state inspection and tightening federal rules around mass compounding both point to real safety gaps worth taking seriously. Before you order compounded semaglutide or tirzepatide from Aequita or any similar pharmacy, confirm you have a genuine, individualized prescription, understand the dosing format you’ll receive, and ask direct questions about the active ingredient and quality testing. If the safety tradeoffs give you pause, compare your options against brand-name GLP-1 drugs or other reviewed providers, such as the compounded semaglutide and tirzepatide injection options outlined here, before you commit to a subscription.

This article is for informational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting or changing any medication.

References

1. Mochi Health Weight Loss Drugs Scrutinity. nbcbayarea.com.
2. FDA Clarifies Policies Compounders National Glp 1 Supply Begins Stabilize. fda.gov.
3. FDA Clarifies Policies Compounders National Glp 1 Supply Begins Stabilize. fda.gov.
4. Glp 1 Medications for Weight Loss Safety Side Effects Compounded Drugs and Access. ncoa.org.
5. FDA Raises Safety Concerns with Compounded Glp 1 Weight Loss Drugs. everydayhealth.com.
6. FDA Telehealth Companies What Know When Promoting Compounded Drugs. fda.gov.
7. What Are the Safety Concerns Regarding Compounded Glp 1 Receptor Agonists. dig.pharmacy.uic.edu.
8. Healthcare Stakeholders Glp 1 Compounding. us.milliman.com.
9. Pmc12331335. pmc.ncbi.nlm.nih.gov.